Collegium Pharmaceutical Inc(COLL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:42 AM ET (Korea 9/11 17:42)
Full metrics table
| Index | RUT | P/E | 18.57 | EPS (ttm) | 1.23 | Insider Own | 2.19% | Shs Outstand | 32.5M | Perf Week | -5.68% |
| Market Cap | 0.75B | Forward P/E | 3.46 | EPS next Y | -10.25% | Insider Trans | -4.21% | Shs Float | 31.8M | Perf Month | -11.78% |
| Enterprise Value | 1.81B | PEG | - | EPS next Q | 1.82 | Inst Own | 125.8% | Short Float | 20.49% | Perf Quarter | -34.14% |
| Income | 0.05B | P/S | 0.92 | EPS this Y | -0.67% | Inst Trans | 1.92% | Short Ratio | 10.43 | Perf Half Y | -35.65% |
| Sales | 0.81B | P/B | 2.39 | EPS next 5Y | -5.17% | ROA | 2.57% | Short Interest | 6.52M | Perf YTD | -50.5% |
| Book/sh | 9.6 | P/C | 5 | EPS past 3/5Y | - 17.92% | ROE | 17.61% | 52W High | -54.87% ($50.79) | Perf Year | -39.22% |
| Cash/sh | 4.59 | P/FCF | 2.27 | Sales past 3/5Y | 18.94% 20.28% | ROIC | 3.25% | 52W Low | -0.82% ($23.11) | Perf 3Y | -3.66% |
| Dividend Est. | - | EV/EBITDA | 4.58 | EPS Y/Y TTM | 34.35% | Gross Margin | 60.02% | Volatility(W/M) | 3.77% 4.35% | Perf 5Y | 16.35% |
| Dividend TTM | - | EV/Sales | 2.25 | Sales Y/Y TTM | 14.31% | Oper. Margin | 20.12% | ATR (14) | 1.22 | Perf 10Y | 145.66% |
| Dividend Ex-Date | - | Quick Ratio | 0.84 | EPS Q/Q | -234.56% | Profit Margin | 5.93% | RSI (14) | 22.66 | Recom | 1.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.03 | Sales Q/Q | 6.32% | SMA20 | -11.89% ($26.01) | Beta | 0.72 | Target Price | $48.86 |
| Payout | - | Debt/Eq | 3.9 | Earnings | 2026/8/6 | SMA50 | -26.22% ($31.07) | Rel Volume | 1.39 | Prev Close | $23.36 |
| Employees | 423 | LT Debt/Eq | 3.72 | EPS/Sales Surpr. | 11.69% 0.13% | SMA200 | -39.26% ($37.73) | Avg Volume(3M) | 0.63M | Price | $22.92 |
| IPO | 2015/5/7 | Option/Short | Yes/Yes | Trades | 10580 | Volume | 866,402 | Change | -1.88% |
Company
COLL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Collegium Pharmaceutical (COLL) is a diversified specialty pharmaceutical company focused on pain management. It holds Xtampza extended-release tablets, built on its abuse-deterrent DETERx technology platform, and the Nucynta franchise as core assets, and has recently expanded its portfolio by adding assets in the attention-deficit/hyperactivity disorder (ADHD) space. The company is dedicated to prescription medications for patients with serious conditions, including chronic pain.
Over the past 1 year, on the lower side
55% below its 1-year high.
COLL makes money exceptionally well
20.12% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -0.7% this year.
Tap to view numbers
The stock looks undervalued
Trading at 18.6 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -3.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 125.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ABLS 0.04%
PJP 0.02%
PBE 0.02%
LFSC 0.02%
MGMT 0.02%It ranks #4 in the industry
Based on market cap of $746M.
COLL $746M PER 18.6
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is COLL?
COLL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of COLL?
The market cap of COLL is approximately $746M, ranking 2,877 within its sector.
What is the P/E ratio of COLL?
COLL has a P/E ratio of approximately 18.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for COLL?
COLL has recorded a 52-week high of $50.79 and a low of $23.11.
